The experimental therapy Bravyl significantly reduced the spread of toxic TDP-43 protein clumps in a cell model of ALS.

Worrying about symptom progression a year after her diagnosis, columnist Dagmar Munn decided to develop her own resilience ...

The delay in diagnosing ALS means treatment and supportive care is received later, which can have a significant impact on ...

Columnist Juliet Taylor's late husband, Jeff, always made Christmas special. To honor his memory, she carries on their ...

The U.S. Food and Drug Administration (FDA) signaled that it may be willing to consider granting accelerated approval to ...

Growing up in rural areas, having younger parents, and having less education may all be environmental risk factors for ALS, ...

MN-166 (ibudilast) appears to benefit ALS patients over up to one year of use, an interim Phase 2b/3 trial analysis suggests.

Help for family caregivers is urgently needed in the U.S., as the current situation is untenable, writes columnist.

The U.S. Food and Drug Administration (FDA) signaled that it may be willing to consider granting accelerated approval to CNM-Au8 to treat amyotrophic lateral sclerosis (ALS), based on data from ...